Kailera Therapeutics Stifel 2026 Healthcare Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Okay. All right, great. Thank you very much for joining us today. We're having the Kailera session now, developing a whole portfolio of incretins for obesity. With us today is Ron Renaud, CEO of Kailera, and I will step aside and let you give the presentation, and we'll open it up to Q&A.
Terrific. Thanks, Annabel, and good afternoon. Thanks for joining us. I know it's the end of a long day, and again, thanks to Stifel for having us at this terrific conference. As Annabel said, I'm Ron Renaud. I'm the CEO here at Kailera, and this afternoon, I just want to take a few moments to share what we're working on at Kailera, as we believe we have one of the most consequential pipelines in obesity, with four clinical-stage therapies. I think it's a breadth that really reflects a deliberate strategy you're going to hear me talk about today, focused on meeting patients' needs, no matter where they are in their weight loss journey. I'm going to share our progress that we've made to date, and then I'm going to preview a little bit of what's coming. Let's see here. Before I start, just going to make everybody here aware and out there listening that we'll be making forward-looking statements in today's presentation.
I know people are very familiar with the obesity marketplace, the landscape, the incretin market, and landscape, but I think what is still widely overlooked is that obesity remains one of the largest unmet healthcare needs globally. There are more than 1 billion people living globally with obesity, and I think this is often forgotten. Current therapies have definitely shown what's possible, and have made a significant impact, but obesity remains a chronic disease that is drastically undertreated, and treatment rates, believe it or not, still remain in the high single digit to low double digit range.
At Kailera, we really based on this and the pipeline and portfolio that we have and the things that we're working on, we see a substantial opportunity for differentiated medicines that address the diverse needs of people living with obesity, especially the folks that are looking for greater weight loss, improved tolerability, and really starting to think about options that are tailored to individual needs. We have a diversified pipeline with four clinical-stage programs, spanning oral and injectable formats, and single, dual, and triple agonist approaches with extensive clinical evidence generated to date. I'm going to walk you through each of those programs in just a few moments, starting with our potentially category-leading dual agonist we call ribupatide. It's also important to point out that our partnership with Hengrui is a very important part of the Kailera story.
As you think about everything that we're working on here, think about the access, early access to robust clinical datasets, rapid development capabilities, and optionality across mechanisms. Having this collaboration with Hengrui and being able to work with them and their data generation and their collaboration really enables us to make well-informed, risk-adjusted capital allocation decisions. This is evidenced by the fact that in a very short amount of time, we've been out of stealth mode for only two years. This company was a business plan about two and a half years ago. In a very, very short amount of time, we've had now more than 10,000 patients enrolled across both Hengrui and Kailera's trials, which I think gives you some idea of the scope and the speed at which we can operate and the speed at which we can move through global development.
Lastly, none of this progress is possible without execution. Terrific leadership team, a team that's been there and done that, a board that brings deep experience, developing commercializing metabolic disease therapies, and we've got a great group of world-class investors. Let me just take you, before we jump into the pipeline, let me take you through the market opportunity here, because it changes almost on a weekly basis, and it's on the right trajectory. The global obesity market is projected to grow more than $200 billion, to more than $200 billion by 2030. As I think about where we were thinking about Kailera 2 years ago, where the market sales are today is what we thought it was going to be in 2030. We have just seen a real logarithmic shift in market expectations here.
This growth is not just driven by what we see here in terms of near-term demand, but we really see structural tailwinds, not just this utilization, as I mentioned. We see expanding treatment rates globally. More than 20 million Medicare beneficiaries alone are eligible for coverage through the Bridge program. We see the potential for oral therapies to bring new patients into the category, and again, continued market expansion outside of the U.S. Moreover, I think each patient living with obesity is going to be likely to use multiple therapies over their lifetime and in their weight loss journey. These all represent distinct growth opportunities and are happening in parallel. The market is still in early days, as I mentioned.
If you look at the market, the players who are currently on the market, they talk about this all the time, that the market is still in very, very early days and is still significantly under-penetrated. I think it's important to focus on where that growth is coming from and what is the primary treatment choice. These are the dual agonists. This is GLP-1, GIP-based therapies at more than 85% of the market. Yet again, penetration still remains very low in the high single digits to just around 10%. The scale of this opportunity and the fact that the growth is coming from multiple, largely independent sources of demand, I think gives you some sense of where the room for multiple differentiated opportunities for new therapies to succeed comes from. Let me talk a little bit about our pipeline and how we see that fitting in.
Our strategy at Kailera is based on the belief that obesity is not a one-size-fits-all disease and is going to require innovation across multiple patient populations in the obesity landscape. We are uniquely positioned with our lead program, ribupatide, having compelling data both as an injectable and as an oral therapy. For patients living with a BMI of 35 or higher, greater weight loss remains a significant unmet need. Injectable therapies are likely to remain foundational for this patient population, and we believe ribupatide has the potential to offer a category-leading profile given the promising data that we have seen together with our colleagues at Hengrui to date. For patients with lower BMIs or those that are new to GLP-1 therapy, tolerability is often the key to long-term treatment success. We are already seeing this. We are seeing this almost in real time.
Oral therapy is expanding the market by bringing new patients into treatment, and it is going to serve as a stepping stone truly for injectables over time. Across most of these oral therapies, there is a pretty tight band of efficacy around most of these oral therapies at about 10%-15% weight loss, which means that the real differentiation for these oral approaches is going to be tolerability. I think it is going to be absolutely the key differentiator, and this is where our oral ribupatide program has the potential to offer a very, very highly differentiated profile, and I am going to share data from both of these programs in just a moment.
We also have an oral small molecule, which we are now calling safiglipron, which is in phase II, and we also have another potential high-efficacy injectable in our tri-agonist, our triple G for short, which we call KAI-4729. It is also important to point out that all four of our programs are in development under FDA-authorized INDs. These are all being run by Kailera under FDA-authorized INDs. Again, I think as you hear me walk through the pipeline here, you can see that we are really, really focused on trying to meet every patient with obesity, no matter where they are in their weight loss journey. Let us take a little bit of a more close look at our pipeline.
We recently had our third quarter update, and I think for anybody that listened to it, you could see it was another period of continued strong execution across all four of our clinical stage programs. We had an IPO earlier this year, and we said that we would deliver on a number of things, and we have delivered on every single one of them. We have five trials that are now underway with more than 5,000 participants enrolled. Our lead product candidate, you can see here, is ribupatide. This is a once-weekly injectable GLP-1/GIP receptor dual agonist that we believe offers the potential for the greatest weight loss among obesity management medications. Both our global phase III program, KaiNETIC, and our high-dose phase II-B trial are now fully enrolled, with data expected in mid-2027 for the phase II-B trial and in mid-2028 for the phase III KaiNETIC program.
We are also expanding the Jiangsu Hengrui franchise by developing a once-daily oral formulation that has demonstrated the potential for compelling weight loss and category-leading tolerability. We are incredibly excited to have completed our end-of-phase II meeting recently with the U.S. FDA and are now on track to begin our global phase III program in the first half of 2027, evaluating doses up to 25 milligrams over 60 weeks. Our second oral product candidate, as I mentioned, is safiglipron. This is a once-daily small molecule GLP-1 receptor agonist. Our phase II trial with that program is also now fully enrolled, and we will have data from that program in the middle of 2027. Then finally, I mentioned to you our triple G, we call KAI-4729. This is a once-weekly injectable GLP-1/GIP/glucagon tri-agonist. As I mentioned, we call it a triple G for short.
We now have an active IND with the U.S. FDA, and we plan to move 4729 into a phase I trial by the end of this year. Again, data from that program sometime in 2027. I think you can see for us, 2027 is absolutely shaping up to be a catalyst-rich year with important milestones from all four of our programs. Let's jump into the lead program, our Jiangsu Hengrui program first. As I mentioned, there has been tremendous progress made in the weight loss category in treating patients living with obesity, with successful branded incretins marketed for the treatment of obesity. But we do know that this market, despite these additions, continues to grow, and it is growing at a rate that is probably higher than you would expect with the addition of these therapies.
We know that half of all Americans by 2030 are going to be living with some level of obesity. I think in this patient population, I think what is more staggering is that more than 60 million U.S. adults, or roughly half of all the patients living with obesity in 2030, are going to have a BMI of 35 or greater. These patients clearly need more weight loss than what today's therapies are going to provide. If we go back and we look at Lilly's SURMOUNT-1 study, this was a phase III study, we know that 68% of participants who started in that study with a BMI of 35 or higher were still living with obesity after 72 weeks of tirzepatide.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
